/OBIO
OBIO Stock - Orchestra BioMed Holdings, Inc.
Healthcare|BiotechnologyNASDAQ
$4.35+0.23%
+$0.01 (+0.23%) • Dec 19
86
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.88
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.95
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+175.9%upside
Target: $12.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for OBIO
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$4.31 – $4.39
TARGET (TP)$12.00
STOP LOSS$4.00
RISK/REWARD1:21.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta0.62
52W High$6.30
52W Low$2.20
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $2.64M | $2.76M | $3.53M | $-782,000 | $5.70M |
| Gross Profit | $2.43M | $2.57M | $3.21M | $-981,000 | $5.56M |
| Gross Margin | 92.3% | 93.3% | 90.9% | 125.4% | 97.5% |
| Operating Income | $-64,301,000 | $-51,506,000 | $-32,657,000 | $-21,799,000 | $-18,752,000 |
| Net Income | $-61,024,000 | $-49,120,000 | $-33,608,000 | $-23,014,000 | $-21,355,000 |
| Net Margin | -2313.3% | -1779.7% | -951.3% | 2943.0% | -374.5% |
| EPS | $-1.66 | $-1.48 | $-1.32 | $-0.02 | $-0.01 |
Company Overview
Orchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.
Visit WebsiteRating Distribution
Strong Buy
0%
Buy / Outperform
6
86%
Hold / Neutral
1
14%
Sell / Underperform
0%
Analyst Consensus🟢 Bullish
6 Bullish1 Neutral/Bearish
Price Targets
$15
Average Target
↑ 247.7% Upside
Now
$12
Low
$15
Average
$20
High
Based on 8 analysts
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| December 10th 2025 | TD Cowen | Initiation | Buy | $15 |
| August 20th 2025 | BTIG Research | Downgrade | Neutral | - |
| March 20th 2025 | BTIG Research | Initiation | Buy | $12 |
| January 2nd 2025 | Barclays | Initiation | Overweight | $16 |
| August 22nd 2024 | H.C. Wainwright | Initiation | Buy | $14 |
| July 25th 2024 | B. Riley Securities | Initiation | Buy | $15 |
| January 19th 2024 | Jefferies | Initiation | Buy | $14 |
| February 24th 2023 | Piper Sandler | Initiation | Overweight | $15 |
| February 7th 2023 | Chardan Capital Markets | Initiation | Buy | $20 |
Earnings History & Surprises
OBIOBeat Rate
67%
Last 12 quarters
Avg Surprise
+6.1%
EPS vs Estimate
Beats / Misses
8/3
1 met exactly
Latest EPS
$-0.40
Q4 2025
EPS Surprise History
Q1 24
+2.6%
$-0.37vs$-0.38
Q2 24
+5.0%
$-0.38vs$-0.40
Q3 24
-9.8%
$-0.45vs$-0.41
Q4 24
+6.8%
$-0.41vs$-0.44
Q1 25
+14.0%
$-0.37vs$-0.43
Q2 25
0.0%
$-0.43vs$-0.43
Q3 25
+2.0%
$-0.50vs$-0.51
Q4 25
-5.3%
$-0.40vs$-0.38
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 30, 2026 | $-0.38 | — | — | — |
Q4 2025 | Nov 10, 2025 | $-0.38 | $-0.40 | -5.3% | ✗ MISS |
Q3 2025 | Aug 12, 2025 | $-0.51 | $-0.50 | +2.0% | ✓ BEAT |
Q2 2025 | Apr 2, 2025 | $-0.43 | $-0.43 | 0.0% | = MET |
Q1 2025 | Mar 26, 2025 | $-0.43 | $-0.37 | +14.0% | ✓ BEAT |
Q4 2024 | Nov 12, 2024 | $-0.44 | $-0.41 | +6.8% | ✓ BEAT |
Q3 2024 | Aug 12, 2024 | $-0.41 | $-0.45 | -9.8% | ✗ MISS |
Q2 2024 | May 13, 2024 | $-0.40 | $-0.38 | +5.0% | ✓ BEAT |
Q1 2024 | Mar 27, 2024 | $-0.38 | $-0.37 | +2.6% | ✓ BEAT |
Q4 2023 | Nov 13, 2023 | $-0.39 | $-0.38 | +2.6% | ✓ BEAT |
Q3 2023 | Aug 10, 2023 | $-0.42 | $-0.35 | +16.7% | ✓ BEAT |
Q2 2023 | May 12, 2023 | $-0.28 | $-0.40 | -42.9% | ✗ MISS |
Q1 2023 | Jan 25, 2023 | $-0.43 | $-0.08 | +81.8% | ✓ BEAT |
Q4 2022 | Dec 16, 2022 | — | $-0.05 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.25 | — | — |
Q1 2022 | Mar 31, 2022 | — | $-0.18 | — | — |
Q4 2021 | Dec 31, 2021 | — | $-0.00 | — | — |
Q3 2021 | Sep 30, 2021 | — | $-0.00 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.00 | — | — |
Q1 2021 | Mar 31, 2021 | — | $-0.01 | — | — |
Latest News
TD Cowen Initiates Coverage On Orchestra BioMed Hldgs with Buy Rating, Announces Price Target of $15
📈 PositiveBenzinga•Dec 10, 2025, 04:03 PM
Orchestra BioMed Highlights Strategic Collaboration With Medtronic And Progress Of AVIM Therapy And Virtue SAB At 2025 ICI Meeting
📈 PositiveBenzinga•Dec 8, 2025, 12:12 PM•Also:
Chardan Capital Maintains Buy on Orchestra BioMed Hldgs, Maintains $20 Price Target
📈 PositiveBenzinga•Nov 13, 2025, 01:54 PM
Barclays Maintains Overweight on Orchestra BioMed Hldgs, Lowers Price Target to $11
➖ NeutralBenzinga•Nov 12, 2025, 03:57 PM•Also:
Orchestra BioMed Hldgs Q3 EPS $(0.40) Beats $(0.42) Estimate, Sales $861.000K Beat $757.600K Estimate
📈 PositiveBenzinga•Nov 10, 2025, 09:32 PM
Orchestra BioMed May Offer Up To 8,027,890 Shares Of Common Stock By Selling Stockholders
➖ NeutralBenzinga•Oct 31, 2025, 09:19 PM
Orchestra BioMed Enters $30M Agreement With Terum To Treat Coronary Artery Disease Globally
📈 PositiveBenzinga•Oct 28, 2025, 12:05 PM
Orchestra BioMed Announces First Patient Enrollments In Virtue SAB In Treatment Of Coronary ISR Trial
📈 PositiveBenzinga•Oct 27, 2025, 01:04 PM
Orchestra Biomed To Present Data Summary Supporting Transformative Potential Of AVIM Therapy In Management Of Hypertensive Heart Disease At Georgia Innovation Summit In Tbilisi
📈 PositiveBenzinga•Oct 9, 2025, 12:06 PM
OBIO Highlights Long-Term Durability Of AVIM Therapy In Major Clinical Publications And HRX 2025 Presentation
📈 PositiveBenzinga•Sep 22, 2025, 02:10 PM
Orchestra BioMed Reports Long-Term, Reversible Blood Pressure Benefits Of AVIM Therapy; Results Support Durable, Programmable Treatment For Uncontrolled Hypertension
📈 PositiveBenzinga•Sep 4, 2025, 09:01 PM
HC Wainwright & Co. Maintains Buy on Orchestra BioMed Hldgs, Lowers Price Target to $10
📈 PositiveBenzinga•Sep 4, 2025, 11:33 AM
Orchestra BioMed Holdings shares are trading higher after the company announced the publication of data in the Journal of the American College of Cardiology: Clinical Electrophysiology from a pressure-volume loop study demonstrating favorable hemodynamic effects of AVIM therapy in pacemaker-indicated patients with uncontrolled hypertension.
📈 PositiveBenzinga•Aug 26, 2025, 04:53 PM
Orchestra BioMed And Medtronic Collaboration Advances AVIM Therapy As JACC Data Validates Favorable Hemodynamic Effects And Potential To Reshape Hypertension Care
📈 PositiveBenzinga•Aug 26, 2025, 11:35 AM•Also:
BTIG Downgrades Orchestra BioMed Hldgs to Neutral
📉 NegativeBenzinga•Aug 20, 2025, 11:20 AM
Orchestra BioMed launches public offering; shares down 16%
📉 NegativeSeeking Alpha•Jul 31, 2025, 08:14 PM
Frequently Asked Questions about OBIO
What is OBIO's current stock price?
Orchestra BioMed Holdings, Inc. (OBIO) is currently trading at $4.35 per share. The stock has moved +0.23% today.
What is the analyst price target for OBIO?
The average analyst price target for OBIO is $12.00, based on 1 analyst.
What sector is Orchestra BioMed Holdings, Inc. in?
Orchestra BioMed Holdings, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is OBIO's market cap?
Orchestra BioMed Holdings, Inc. has a market capitalization of $0.25 billion, making it a small-cap company.
Does OBIO pay dividends?
No, Orchestra BioMed Holdings, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorAVTX
Avalo Therapeutics, Inc.
$18.60
Mkt Cap: $0.2B
CRBU
Caribou Biosciences, Inc.
$1.68
Mkt Cap: $0.2B
ENTA
Enanta Pharmaceuticals, Inc.
$15.39
Mkt Cap: $0.3B
EPRX
Eupraxia Pharmaceuticals Inc.
$6.56
Mkt Cap: $0.2B
IVA
Inventiva S.A.
$4.21
Mkt Cap: $0.2B
IVVD
Invivyd, Inc.
$2.30
Mkt Cap: $0.3B
PRLD
Prelude Therapeutics Incorporated
$2.14
Mkt Cap: $0.2B
PYXS
Pyxis Oncology, Inc.
$1.27
Mkt Cap: $0.1B
TARA
Protara Therapeutics, Inc.
$5.27
Mkt Cap: $0.2B
TNYA
Tenaya Therapeutics, Inc.
$0.70
Mkt Cap: $0.1B
Explore stocks similar to OBIO for comparison